Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.61 |
| ▸ | HTR2B | P41595 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977616 | 0.95 | HSD11B1 (0.65) | HSD11B1HTR2BPTPN1KDM4EMEN1 | |
| SCHEMBL3638448 | 0.87 | HSD11B1 (0.56) | HSD11B1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL13952158 | 0.87 | HSD11B1 (0.54) | HSD11B1HTR2BPTPN1MEN1KMT2A | |
| SCHEMBL24628704 | 0.87 | MGLL (0.52) | HTR2BMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL8157501 | 0.87 | SMN1; SMN2 (0.65) | HSD11B1HTR2BMEN1KMT2AALDH1A1 | |
| SCHEMBL8161198 | 0.86 | HSD11B1 (0.51) | HSD11B1HTR2BPTPN1MEN1KMT2A | |
| SCHEMBL8168302 | 0.83 | PDE4B (0.57) | HSD11B1HTR2BALDH1A1L3MBTL1LMNA | |
| SCHEMBL8160698 | 0.83 | HSD11B1 (0.66) | HSD11B1HTR2BPTPN1KDM4EMEN1 | |
| SCHEMBL22875343 | 0.82 | HSD11B1 (0.63) | HSD11B1HTR2BKDM4EMEN1KMT2A | |
| SCHEMBL3501319 | 0.81 | HSD11B1 (0.61) | HSD11B1HTR2BKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM3 | HSD11B1 3573/4885HTR2B 84/4885PTPN1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.